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Abstract
Background: Diabetic nephropathy (DN) is one of the leading causes of death in patients with type 2 diabetes mellitus
(T2DM). Several genome-wide association studies have introduced Engulfment and Cell Motility 1 (ELMO1) as a
candidate gene which is associated with DN. This study assessed the association of ELMO1 gene polymorphisms with
DN in order to investigate the effects of ELMO1 gene on susceptibility to DN in an Iranian population.
Methods: In the present study, 100 patients with T2DM, 100 patients with DN and 100 healthy subjects who were
matched for sex were selected. Allele and genotype frequencies were determined by Tetra-ARMS PCR technique. In all
groups, levels of FBS, creatinine, urea, HbA1C, urine levels of albumin creatinine ratio and glomerular filtration rate were
measured.
Results: A statistically significant association was shown between G allele of rs741301 (odds ratio (OR) = 1.7 [95 % CI 1.
17–2.63]; p value = 0.005), and GG genotypes of rs741301 (OR = 2.5 [95 % CI 1.2–5.4]; p value = 0.01) and DN. A significant
association was not detected between allelic and genotypic frequencies of rs1345365 and DN. Linkage Disequilibrium
(LD) between two variants was weak (D' = 0.11, r2 = 0.008). rs1345365A/rs741301A haplotypes were more frequent in
patients with T2DM as compared to DN (OR = 0.5 [95 % CI 0.3–0.7]; p value = 0.0006). Also, genotypes of variant rs741301
in all subjects had significant difference with respect to the mean of ACR (p Value < 0.05).
Conclusion: This study first investigated the association of ELMO1 gene polymorphisms (rs741301) with DN in an Iranian
population, supporting its key role as a candidate gene in the susceptibility to DN.
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Background
Type 2 diabetes mellitus (T2DM) has become a silent
pandemic over the past few decades, resulting in remark-
able loss in government’s economy, and has endangered
human health [1, 2]. Patients with diabetes mellitus all
over the world were estimated to be 173 million cases in
2002 and are anticipated to increase to 350 million cases
by 2030 [3]. Microvascular complications of diabetes such
as Diabetic Nephropathy (DN) can play a significant
role in mortality of diabetes. DN as a progressive kid-
ney disease affects almost 35 % of the diabetic patients
irrespective of glycemic control [4]. It is the leading cause
of kidney failure and end-stage renal disease worldwide
[5] and also the most common cause of kidney transplant
in Iran [6]. Further, patients with DN have an increased
risk of cardiovascular mortality [7]. It is estimated that an-
nual costs of hemodialysis treatment for each patient are
an average of 11000 dollars in Iran [8, 9]. DN has been de-
fined as increased protein excretion in urine and in lack of
any kind of kidney disease [10].
Nowadays, it is generally accepted that DN is a multifac-
torial progressive disorder caused by the cooperation
between environmental factors and genetic factors. The
most important risk factors such as hyperglycemia, hyper-
tension, diabetic duration, hyperlipidemia, chronic inflam-
mation, familial clustering and genetic determinants can
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make a diabetic patient susceptible to DN. However, no
clear etiology and pathogenesis have been found [11–13].
Outbreak of DN between ethnic groups and familial cluster-
ing affirms the presence of a genetic component [14–17].
Main part of the research on DN evaluates the genetic role
in DN pathogenesis because elucidation of genes associated
with DN can help for better understanding of disease
molecular mechanism, complications, prevention and treat-
ment [12]. As a result, early identification and more severe
therapies can reduce the outcome of DN.
Genome-Wide Association Studies (GWAS) have re-
ported some important genes all around the globe for re-
sistance or susceptibility to DN [18]. ELMO1 (Engulfment
and Cell Motility 1) as a new and strong candidate gene, lo-
cated on chromosome 7p14.2-14.1, is used for cell motility
and phagocytosis of apoptotic cells [19]. In spite of this, the
precise role of ELMO1 in the development and progression
of nephropathy attributed to T2DM is still unknown.
The first GWAS was conducted in Japanese individ-
uals in 2005; over 80,000 SNP loci were evaluated and
one SNP locus in the 18th intron of the ELMO1 gene
was found to be strongly associated with DN [20]. Later
studies have demonstrated that variants in the ELMO1
gene are associated with kidney disease attributed to
T2DM in American Indians [21], European Americans
[22] and Chinese population [23]. Also, recently large
African American cohorts with type 2 diabetes have sug-
gested that SNPs locus in the 13th intron of the ELMO1
gene was detected to be associated with DN [24]. Compli-
cations of T2DM are demonstrated to be more common
among Asians compared to Western people [25] and this
study was performed for the first time in Iran. The aim of
the present study was to evaluate the possible association
between the variants rs741301, rs1345365 and DN in a
sample of the Iranian population.
Methods
Study subjects
This case–control study was performed between January
and December 2015 in the Diabetes and Metabolic re-
search Center affiliated to Endocrinology and Metabol-
ism Research Institute (EMRI) of Tehran University of
Medical Sciences (TUMS), Tehran, Iran. A total of 200
patients with T2DM were enrolled in the study that included
100 patients with nephropathy (DN) and 100 patients with-
out nephropathy (DM). A control group consisting of 100
healthy controls (HC) was also included. T2DM was diag-
nosed by the criteria of the American Diabetes Association
(ADA) [26]. Subjects with urinary albumin/creatinine ratio
(ACR) ≥30 mg/g and protein excretion history caused
by diabetes were considered as the DN group. DM group
was indicated by ACR < 30 mg/g and ADA criteria for
diabetes. Subjects of the control group were healthy popu-
lation without diabetes and any kind of kidney disease.
Exclusion criteria in the present study were: subjects of
non-Iranian origin, patients with Type 1diabetes, diabetes
duration less than 5 years, HbA1C > 9 %, urinary tract in-
fection, uncontrolled hypertension, pregnancy, hematuria,
smoking and any other cause of protein excretion except
diabetes type 2. Ages of subjects in all the population were
between 35 and 75. The groups were matched for sex.
The study was approved by the Ethics Committee of
EMRI. After describing the aims of the study, a written
informed consent was acquired from each subject.
Clinical characteristics of subjects
Several demographic and anthropometric measurements
were taken. Blood pressure was measured after 20 min
of rest. The weight and the height were measured and
the body mass index (BMI) was calculated (kg/m2). Urine
and fasting blood samples were obtained from the subjects
for biochemical analysis and DNA extraction. Glycosyl-
ated hemoglobin (HbA1C) (TOSOH G8, Tokyo, Japan)
and Fasting Blood Sugar, urea, creatinine, and also urine
albumin creatinine ratio (Pars Azmun, Tehran, Iran) were
measured. Estimated glomerular filtration rate (eGFR) was
calculated using Cockroft and Gault equation [27].
Genotyping
We selected the variants rs741301 and rs1345365 of
ELMO1 gene, which were presented as common SNPs
by some considerable genome-wide association studies
(GWAS) in other populations. Genomic DNA was extracted
from peripheral blood lymphocytes in the buffy coat using
Bio Basic DNA isolation kit (Bio Basic Inc., Markham,
Canada) in accordance with manufacturer’s instructions.
The quantity and quality of DNA were examined with
spectrophotometer and electrophoresis. SNPs genotyping
was carried out by tetra-ARMS-PCR, which is a rapid, re-
liable, and cost-effective method for the detection of SNPs
[28, 29]. Outer and inner primers are shown in Table 1.
PCR product sizes for the variant rs741301 polymorphism
were: 407 bp for two outer primers (control bands),
187 bp for G allele and 273 bp for A allele. Also, prod-
uct sizes in order to check the variant rs1345365 poly-
morphism were: 692 bp for two outer primers (control
bands), 284 bp for G allele and 461 bp for A allele. PCR
for ELMO1 amplification was carried out in 0.2 ml
tubes which totally contain 25 μL reaction mixture. The
reaction mixture was made by adding 2 μL template
DNA, 1 μL for inner primers and 0.5 μL for outer primers
(10 μM), 12.5 μL available PCR premix (Taq DNA Poly-
merase Master Mix Red, Ampliqon, Skovlund, Denmark)
according to the manufacturer recommended protocol
and 7.5 μL distilled water. The PCR cycling condition for
the detection of the variant rs741301 polymorphism was
95 °C for 5 min followed by 35 cycles, including denatur-
ation at 94 °C for 35 s, annealing at 63.5 °C for 30 s, and
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extension at 72 °C for 40s. The PCR condition for the de-
tection of the variant rs1345365 polymorphism was 5 min
at 95 °C followed by 35 cycles of 35 s at 95 °C, 30 s at
66 °C and 30 s at 72 °C with a final extension at 72 °C
for 5 min in order to complete the extension of all PCR
fragments. The PCR products were detected by electro-
phoresis on a 1.8 % agarose gel. Then, it was visualized
by transillumination with UV light and finally photo
was taken. Negative and positive controls were used in
each genotyping run and 10 % of the randomly selected
samples were re-genotyped in order to verify the initial
results, with 100 % concordance. Also, genotypes were
confirmed by randomly selecting some samples for
DNA Sequencing.
Statistical analysis
Statistical analyses were performed using the SPSS ver-
sion 22.0 software for windows (SPSS Inc, Chicago, IL).
Each SNP was evaluated for Hardy-Weinberg equilibrium
(HWE) by using an HWE calculator [30]. Fisher exact test
was used in order to compare genotypes and alleles be-
tween groups. Mann–Whitney test was used in order to
compute the continuous variables. Odds Ratio (OR)
and the 95 % confidence intervals (CI) were calculated
by using Unconditional logistic regression in order to
examine the association between genotypes and DN.
Also, adjusting for potential confounders such as sex,
age and diabetes duration was performed by Multivari-
ate logistic regression. Clinical parameters of the sub-
jects were evaluated as Mean ± SD. One-way ANOVA
was used in order to calculate the significance of the
difference among the clinical parameters of groups.
HWE, haplotype construction and frequency analysis
were evaluated with SHEsis software [31]. A p value <
0.05 was considered to be statistically significant.
Results
The demographic and clinical characteristics of groups
are shown in Table 2. Age, systolic blood pressure, body
mass index (BMI), duration of diabetes, fasting blood
sugar, HbA1C, serum creatinine, serum urea, and ACR
were higher in DN group compared to DM and HC
groups. Furthermore, eGFR was lower in DN subjects
than DM & HC.
The allele and genotype frequencies of two variants
in diabetic patients and healthy controls are shown in
Tables 3 and 4. Two SNPs had minor allele frequency
of more than 0.05 and were matched with HWE. GG
genotypes and G allele of the variant rs741301 were more
frequent in DN group as compared to DM. Moreover, G
Table 1 Primers used for polymorphism determination of ELMO1
Primers rs741301 rs1345365
Forward inner 5′ATAGCAATAGATTTTATGAGGTGGTAGT 3′ 5′GCCACTTCTTCCCCTACAACATTGA 3′
Reverse inner 5′TCATTAGTGATAACATAACCTCTGGTAG 3′ 5′GCCAGTGAGAGAGTAATACTATTACGTTC3′
Forward outer 5′AGTCTTGAGGATGAATGAATTCTAGG 3′ 5′TGCCATAGGTACTGCTTCTCTGAGT 3′
Reverse outer 5′TGTCCTAACAATTCGTTCATGATTAATG 3′ 5′CTGAAGTCTAGTAAGAGCTCAAGGTCAGT 3′
Table 2 Demographic and clinical characteristics of groups’ subjects
Parameters DN (n = 100)
mean ± SD
DM (n = 100)
mean ± SD
HC (n = 100)
mean ± SD
p value
Age (years) 61.5 ± 8.5 57.36 ± 8.1 50.5 ± 10.7 *A
Duration of diabetes (years) 12.01 ± 7.6 10.20 ± 6.9 - ‡
BMI (Kg/m2) 29.09 ± 5.3 28.7 ± 4.5 27. 94 ± 4.9 ‡
SBP (mmHg) 125 ± 13.08 120.7 ± 20 115.2 ± 12.6 *A
DBP (mmHg) 77.2 ± 8.8 76.5 ± 7.9 79.3 ± 6.2 ‡
FBS (mg/dl) 144.06 ± 54.3 140.6 ± 45 92.4 ± 10.9 *A
HbA1C (%) 7.2 ± 0.70 7.09 ± 0.73 5.5 ± 0.58 *A
creatinine (mg/dl) 1.2 ± 0.41 1.1 ± 0.27 1 ± 0.17 *A
Urea (mg/dl) 42.3 ± 17.3 36.7 ± 13.7 31.3 ± 10.1 *A
eGFR (L/min/1.73 m2) 65.9 ± 20.6 75.2 ± 20.7 78.8 ± 17.3 *B
ACR (μg/mg) 83.3 ± 64.6 23.7 ± 5.5 21.3 ± 7.7 *B
DN Type 2 diabetes with Nephropathy, DM Type 2 diabetic without Nephropathy, HC Healthy control, BMI Body Mass Index, SBP Systolic Blood Pressure,
DBP Diastolic Blood Pressure, eGFR estimated Glomerular Filtration Rate, FBS Fasting Blood Sugar, ACR urine Albumin/Creatinine ratio
*means p value <0.05, ‡ means p value > 0.05, A = Significant difference between DM/DN and HC, B = Significant difference between DN and HC/DM
Serum urea adjusted by age and sex. FBS, HbA1C and serum creatinine adjusted by duration of diabetes
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allele of the variant rs741301 was more frequent in DN as
compared to HC. There was no significant difference in
allele and genotypes frequencies of the variant rs1345365
between DN and DM or between DN and HC. Then, we
applied two SNPs in an unconditional logistic regression
analysis, after checking for age, sex, creatinine, blood pres-
sure, BMI and so on.
Linkage Disequilibrium (LD) between two ELMO1
SNPs, rs741301 and rs1345365 was tested by using SHEsis
software and it was estimated that LD between two
ELMO1 SNPs was weak (D' = 0.11, r2 = 0.008). Also,
haplotypes frequencies were tested between DN and
DM subjects and the results are shown in Table 5.
rs1345365A/rs741301A haplotypes were more fre-
quent in DM as compared to DN and they were found
to be protective against DN. rs1345365A/rs741301G
haplotypes were more frequent in DN as compared to
DM.
Finally, we evaluated the association of several clinical
parameters in all subjects with respect to the variants ge-
notypes. Results showed that each genotype of the variant
rs1345365 in all subjects was not associated with various
clinical parameters. But after using the post-hoc bonferroni
test, we found that GG genotype vs AA or AG genotypes
of the variant rs741301 in all subjects had significantly
higher level of ACR (p value = 0.03).
Discussion
In the present study, we investigated ELMO1as a candi-
date gene for susceptibility to DN in Iranian individuals;
a population with a high incidence of DN. Our analysis
suggested an association between allelic and genotypic
Table 3 Allele and genotypes frequencies distribution of ELMO1 variants in DN and DM subjects
SNP ID Allele/Genotype DN (n = 100)
N (%)
DM (n = 100)
N (%)
p value OR (95 % CI)
rs1345365 A 143 (71.5) 153 (76.5) 0.2 0.7 (0.4–1.2)
G 57 (28.5) 47 (23.5) 0.2 1.2 (0.8–2)
AA 51 (51) 58 (58) 0.3 0.7 (0.4–1.3)
AG 41 (.41) 37 (37) 0.5 1.1 (0.6–2)
GG 8 (8) 5 (5) 0.3 1.6 (0.5–5.2)
HWE 0.9 0.7
rs741301 A 106 (53) 133 (66.5) 0.005 0.5 (0.3–0.8)
G 94 (47) 67 (33.5) 0.005 1.7 (1.17–2.63)
AA 32 (32) 45 (45) 0.05 0.5 (0.3–1)
AG 42 (42) 43 (43) 0.8 0.9 (0.5–1.6)
GG 26 (26) 12 (12) 0.01 2.5 (1.2–5.4)
HWE 0.1 0.7
HWE Hardy-Weinberg equilibrium, DN Type 2 diabetes with Nephropathy, DM Type 2 diabetes without Nephropathy
Table 4 Allele and genotypes frequencies distribution of ELMO1 variants in DN and HC subjects
SNP ID Allele/Genotype DN (n = 100)
N (%)
HC (n = 100)
N (%)
p value OR (95 % CI)
1345365 A 143 (71.5) 138 (69) 0.2 1.1 (0.7–1.7)
G 57 (28.5) 62 (31) 0.2 0.8 (0.5–1.3)
AA 51 (51) 47 (47) 0.3 1.1 (0.6–2)
AG 41 (41) 44 (44) 0.1 0.8 (0.5–1.5)
GG 8 (8) 9 (9) 0.7 0.8 (0.3–2.3)
HWE 0.9 0.7
rs741301 A 106 (53) 129 (64.5) 0.01 0.6 (0.4–0.9)
G 94 (47) 71 (35.5) 0.01 1.6 (1.1–2.5)
AA 32 (32) 44 (44) 0.08 0.5 (0.3–1)
AG 42 (42) 41 (41) 0.8 1 (0.5–1.8)
GG 26 (26) 15 (15) 0.05 2 (1–4.1)
HWE 0.1 0.2
HWE Hardy-Weinberg equilibrium, DN Type 2 diabetes with Nephropathy, HC Healthy Control
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frequencies of the variant rs741301 and susceptibility to
DN. In fact, we detected that G allele (OR = 1.7 [95 % CI
1.17–2.63], p = 0.005) and GG genotype (OR = 2.5 [95 % CI
1.2–5.4] p = 0.01) might predispose an Iranian patient with
T2DM to DN. Over the last decade, GWAS and replica-
tion studies have produced impressive results upon the
genetic basis of DN. GWAS in Japanese type 2 diabetic pa-
tients (546 DN cases and 334 type 2 diabetic controls) [20],
replication studies in GoKinD collection study (558 DN
cases and 820 type 2 diabetes controls) [22] and American
Indian study (107 cases with diabetic ESRD and 108 con-
trol subjects with T2DM) [21], African American cohorts
(1160 controls and 1136 cases include End stage renal dis-
ease and T2DM) [24], Chinese population (123 DN cases
and 77 type 2 diabetic controls) [23] and Indian popula-
tion (202 cases with DN and 215 controls with T2DM)
[32] support the key role of ELMO1 as a susceptible gene
in DN. Although most studies identified ELMO1 as a can-
didate gene for DN, results showed that risk SNPs and risk
allele are not similar in all populations [33].
Most studies represented rs741301 polymorphism as
the strongest SNP associated with DN. In 2005, GWAS
was first done in Japanese T2DM patients and the ob-
tained results identified the strongest association between
rs741301polymorphism and DN. They showed that G al-
lele in rs741301 and GG genotype are associated with risk
of DN in Japanese patients, which is consistent with our
results [20]. Risk allele in rs741301 in Chinese population
was opposite to that identified in our study as the A allele
in rs741301 was associated with risk of DN in Chinese
people whereas in Iranian population, it was a protective
allele for T2DM patients against progressing to DN.
Moreover, a significant difference was found between
DN and DM with respect to allelic and genotypic fre-
quencies of rs741301 and rs10951509 polymorphism
[23]. American-Indian and Mexican-American popula-
tion studies failed to show the significant association
between allelic and genotypic frequencies of the variant
rs741301 and susceptibility to DN [21, 34]. A meta-
analysis of genetic associations in diabetic nephropathy
showed that rs741301 of ELMO1 was associated with
diabetic nephropathy in Asians with type 2 diabetic ne-
phropathy (OR 1.58 [95 % CI 1.28–1.94]) [35]. Indian
population study showed that GG genotype frequencies
were higher in diabetic versus HC groups (p value < 0.05),
which is consistent with our results [32]. The marker
rs741301 located in intron 18 of ELMO1 gene was in
weak Linkage Disequilibrium (LD) with marker rs1345365
located in intron 13 of ELMO1 gene (D' = 0.11, r2 =
0.008), which is consistent with the result of the Chinese
study as two SNPs had weak LD together (D' = 0.3).
Also, in the present study, we did not find any signifi-
cant difference between case and control groups with re-
spect to allelic and genotypic frequencies of the variant
rs1345365 of intron 13, which is consistent with the
Chinese study [23], Mexican study [36] and opposite to
American Indians study as the A allele in rs1345365 was
associated with the increased risk of DN in American In-
dian people. African American cohorts showed that four
SNPs located in intron 13 (rs1345365, rs1981740,
rs10951509 and rs2058730) are associated with T2DM-
ESRD [24]. Haplotypes analysis suggested rs1345365A/
rs741301A as a protective haplotype (OR = 0.5 [95 % CI
0.3–0.7] p value = 0.0006) for Iranian patients with
T2DM against progressing to DN, which is inconsistent
with the Chinese study as this haplotype has been identi-
fied as a risk haplotype for DN [23]. Also, our results
presented rs1345365A/rs741301G as a risk haplotype
(OR = 1.85 [95 % CI 1.1–2.9], p value = 0.006) for Iranian
patients with T2DM progressing to DN. These results
showed that rs741301 polymorphism may play an import-
ant role in increasing the risk of DN. Results of studies
maybe conflicting and the reason may be related to un-
known etiology of DN, multiple genetic factors, envir-
onmental and racial differences and inappropriate
sample sizes.
In 2006, Shimazaki and colleagues found that expression
of ELMO1 gene increased in high glucose conditions.
Subsequently, it terminated to increased expression of
extracellular matrix genes and decreased expression of
metalloproteinase gene and cell adhesive properties might
make diabetes progress to DN. The exact mechanism of
ELMO1 role in expression of these genes is still unknown,
but last studies suggested that ELMO1 cooperates with
Dock180 and they activate Rac-1 and this complex
leads to increased expression of extracellular matrix gene.
Table 5 Haplotypes frequencies of ELMO1 gene polymorphisms between DN and DM subjects
Haplotypes DN (n = 100)
N (%)
DM (n = 100)
N (%)
Chi2 p value OR (95 % CI)
rs1345365A/rs741301A 77 (38.5) 111 (55.5) 11.6 0.0006 0.5 (0.3–0.7)
rs1345365A/rs741301G 66 (33) 42 (21) 7.3 0.006 1.85 (1.1–2.9)
rs1345365G/rs741301A 29 (14.5) 22 (11) 1.1 0.2 1.3 (0.7–2.4)
rs1345365G/rs741301G 28 (14) 25 (12.5) 0.1 0.6 1.14 (0.6–2.03)
DN Type 2 diabetes with Nephropathy, DM Type 2 diabetes without Nephropathy
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Shimazaki showed that there are not significant effects of
these factors on the expression of extracellular matrix
gene [19, 37].
The present study evaluated for the first time the gen-
etic variants of ELMO1 in an Iranian subjects with or
without T2DM. The limitations of this study were the
relatively small sample size, especially in DN group and
also lack of diabetic patients with ESRD.
Conclusions
ELMO1 may play a role in diabetic kidney disease in
Iranian individuals as a population with high prevalence
of T2DM, DN and ESRD. We found that G allele and
GG genotypes of the marker rs741301 may predispose a
diabetic patient to progressing to DN. Also, the association
between the marker rs741301 and mean of ACR implicates
this gene in susceptibility to DN. As a result, ELMO1 could
be selected as an appropriate target in order to prevent
and treat DN.
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